EMMA (Emmaus Life Sciences) Debt-to-Equity: -0.47 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emmaus Life Sciences Debt-to-Equity?

Emmaus Life Sciences EMMA -0.52% Debt-to-Equity is -0.47 as of Mar. 2026. The stock has 6 warning signs investors should review. Among 967 Biotechnology companies, Emmaus Life Sciences ranks worse than 103412.51% on this metric.

Emmaus Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $28.59 Mil. Emmaus Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $3.60 Mil. Emmaus Life Sciences's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-67.86 Mil. Emmaus Life Sciences's debt to equity for the quarter that ended in Mar. 2026 was -0.47.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Emmaus Life Sciences's Debt-to-Equity or its related term are showing as below:

EMMA' s Debt-to-Equity Range Over the Past 10 Years
Min: -4.1   Med: -0.6   Max: 0.32
Current: -0.47

During the past 13 years, the highest Debt-to-Equity Ratio of Emmaus Life Sciences was 0.32. The lowest was -4.10. And the median was -0.60.

EMMA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs EMMA: -0.47

Emmaus Life Sciences  (OTCPK:EMMA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Emmaus Life Sciences Debt-to-Equity Related Terms

Emmaus Life Sciences Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Debt-to-Equity Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.05 -0.90 -0.70 -0.58 -0.51

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.58 -0.53 -0.51 -0.47

EMMA vs PTIX, BZYR, RMTG: Debt-to-Equity Comparison

For the Biotechnology subindustry, Emmaus Life Sciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Emmaus Life Sciences Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Emmaus Life Sciences's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Emmaus Life Sciences's Debt-to-Equity falls into.


Emmaus Life Sciences Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Emmaus Life Sciences's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(28.879 + 3.68) / -63.608
=-0.51

Emmaus Life Sciences's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(28.592 + 3.601) / -67.86
=-0.47

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -0.47 mean?
Emmaus Life Sciences (EMMA) has a Debt-to-Equity of -0.47 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Emmaus Life Sciences and its competitors. According to the industry distribution chart, Emmaus Life Sciences ranks #999999 out of 967 companies in the Biotechnology industry.
Is Emmaus Life Sciences' Debt-to-Equity too high?
Emmaus Life Sciences' current Debt-to-Equity is -0.47. Based on the distribution chart, Emmaus Life Sciences ranks #999999 out of 967 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Emmaus Life Sciences' Debt-to-Equity compare to PTIX and BZYR?
According to the Biotechnology industry distribution chart, Emmaus Life Sciences ranks #999999 out of 967 companies for Debt-to-Equity. This places Emmaus Life Sciences in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 967 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Emmaus Life Sciences and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Emmaus Life Sciences's current Debt-to-Equity is -0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 14% above its estimated fair value. The current Debt-to-Equity is -0.47. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Debt-to-Equity is -0.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.